Tissue genotyping means taking a sample of tumor tissue using methods like surgery or needle biopsy. This way, doctors get detailed information about the tumor’s genetics and can find changes that guide targeted treatments. But there are some problems with this method:
Because of these problems, doctors and scientists wanted other methods that are faster, less invasive, and can show how tumors change over time.
Liquid biopsy assays test parts of the tumor that float in the blood or other body fluids. The main parts checked include:
Because a liquid biopsy uses blood samples, it is less invasive and gives more up-to-date molecular information that goes well with tissue genotyping.
Large studies in the U.S. have shown that liquid biopsies work as well as, or almost as well as, tissue genotyping for many genetic targets. This is especially true in metastatic non-small cell lung cancer (NSCLC). Liquid biopsies can also give results faster than tissue tests, helping start treatments sooner.
Many cancer centers and hospitals in the United States now use both tissue and liquid biopsies together. This combined method offers benefits like:
For those managing medical practices, adopting liquid biopsy testing means making sure labs, electronic records, and communication systems can handle this new type of data efficiently.
New technologies like next-generation sequencing (NGS), microfluidics, and digital PCR have made liquid biopsy tests better at finding small amounts of tumor DNA and rare cancer cells. The cost of NGS in the United States has also come down, so more patients can afford these tests.
Combining data from gene sequences, gene activity, and proteins with help from advanced computer tools and artificial intelligence (AI) allows doctors to get a fuller picture of the tumor. This helps make treatment plans that can change as the tumor changes.
Even though liquid biopsies have clear benefits, some issues still slow down their wide use:
Hospital managers should work with labs, insurance plans, and clinical staff to solve these problems and improve patient care.
One big use of liquid biopsies is watching how cancer treatments work in real time. This is very important for targeted drugs and immune therapies because tumors can change fast.
Liquid biopsies can show:
In lung cancer and other solid tumors, liquid biopsies help manage treatment better, which may lead to better patient results.
Liquid biopsies create lots of complex data. Artificial intelligence (AI) and automated workflows help manage this data in hospitals. This is important in the United States, where healthcare focuses on being efficient and following rules.
IT managers in hospitals can connect AI systems with electronic records to help doctors get clear reports without extra work.
Automation reduces mistakes and speeds up lab work. Machines manage sample handling, DNA/RNA extraction, and test preparation. Automated reports are sent safely and quickly to doctors.
This makes clinical work run smoother by:
Companies like Tempus have helped grow AI-based precision medicine tools. Tempus connects with about 65% of academic medical centers and more than half of cancer doctors in the U.S. Their platforms use liquid biopsy and tissue data to provide full tumor profiles and help match patients to clinical trials.
Cancer centers and practices in the U.S. benefit from these networks and new technology. They can join research projects, clinical trials, and offer the latest treatment choices to patients.
For hospitals and medical groups that want to start using liquid biopsy tests, some things to think about include:
Paying attention to these details helps make liquid biopsy testing successful in medical practices, improving care and financial health.
Liquid biopsies add important information to traditional tissue genotyping and allow doctors to watch cancer treatment effects in real time. Advances in testing methods, AI tools, and clinical networks strengthen their use in U.S. cancer care. By solving challenges and using automation, healthcare providers can offer better personalized medicine, speed up treatment choices, and respond well to changing tumors in their patients.
AI accelerates the discovery of novel targets, predicts treatment effectiveness, identifies life-saving clinical trials, and diagnoses multiple diseases earlier, enhancing personalized patient care through advanced data analysis and algorithmic insights.
Tempus provides an AI-enabled assistant that helps physicians make more informed treatment decisions by analyzing multimodal real-world data and identifying personalized therapy options.
Tempus supports pharmaceutical and biotech companies with AI-driven drug development, leveraging extensive molecular profiling, clinical data integration, and algorithmic models to optimize therapeutic strategies.
The xT Platform combines molecular profiling with clinical data to identify targeted therapies and clinical trials, outperforming tumor-only DNA panel tests by using paired tumor/normal plus transcriptome sequencing.
It uses neural-network-based, high-throughput drug assays with light-microscopy to predict patient-specific drug response heterogeneity across various solid cancers, improving treatment personalization.
Liquid biopsy assays complement tissue genotyping by detecting actionable variants that might be missed otherwise, providing a more comprehensive molecular and clinical profiling for patients.
~65% of US Academic Medical Centers and over 50% of US oncologists are connected to Tempus, enabling wide adoption of AI-powered sequencing, clinical trial matching, and research partnerships.
Tempus One is an AI-enabled clinical assistant integrated into the Electronic Health Record (EHR) system, allowing custom query agents to maximize workflow efficiency and streamline access to patient data.
xM is a liquid biopsy assay designed to monitor molecular response to immune-checkpoint inhibitor therapy in advanced solid tumors, offering real-time treatment response assessment.
Fuses combines Tempus’ proprietary datasets and machine learning to build the largest diagnostic platform, generating AI-driven insights and providing physicians a comprehensive suite of algorithmic tests for precision medicine.
Simbo is using AI agents to automate all phone related workflows. Connect now to know more.
Schedule AI Agents Demo Now© Since 2019, Simbo AI.
